General Announcement::Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
01-Aug-2017 12:51:21
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830
Announcement Reference
SG170801OTHR8KZM
Submitted By (Co./ Ind. Name)
For Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
01/08/2017 10:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis GBR 830 is an Investigational, First-in-Class, Anti-OX40 Monoclonal Antibody

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

Press Release_01082017.pdf
Total size =899K